SCM
ENTA icon

Sterling Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Sterling Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.99K Sell
342
-561
-62% -$7.54K ﹤0.01% 2613
2026
Q1 		$11.4K Sell
903
-669
-43% -$8.97K ﹤0.01% 2301
2025
Q4 		$24.8K Buy
1,572
+181
+13% +$2.3K ﹤0.01% 2111
2025
Q3 		$16.6K Buy
1,391
+853
+159% +$6.82K ﹤0.01% 2231
2025
Q2 		$4.07K Buy
538
+177
+49% +$1.06K ﹤0.01% 2624
2025
Q1 		$1.99K Sell
361
-321
-47% -$1.98K ﹤0.01% 2607
2024
Q4 		$3.92K Buy
682
+618
+966% +$5.92K ﹤0.01% 2560
2024
Q3 		$663 Buy
+64
New +$837 ﹤0.01% 2740

Other funds holding ENTA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Sterling Capital Management's ENTA Position: Q2 2026 in Review

Sterling Capital Management reduced its Enanta Pharmaceuticals (ENTA) stake by 62% in Q2 2026, selling an estimated $7.54K and leaving 342 shares worth $4.99K. The position accounts for ﹤0.01% of the portfolio, ranked #2613.

Sterling Capital Management first reported a position in ENTA in Q3 2024 and has held it in 8 quarters since. The position peaked at $24.8K in Q4 2025. 123 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

  • Sterling Capital Management held 342 shares of Enanta Pharmaceuticals worth $4.99K as of Q2 2026.
  • Sterling Capital Management sold 561 Enanta Pharmaceuticals shares in Q2 2026, an estimated $7.54K.
  • Enanta Pharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2613 holding.
  • Sterling Capital Management first reported a position in Enanta Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Enanta Pharmaceuticals position peaked at $24.8K in Q4 2025.
  • 123 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.